Hiraizumi, Kenji
Honda, Chikara
Watanabe, Ayu
Nakao, Takafumi
Midorikawa, Shuichi
Abe, Hiromi
Matsui, Nobuki
Yamamoto, Tsunehisa
Sakamoto, Takahiko http://orcid.org/0000-0002-3518-9574
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan
https://doi.org/10.1007/s10147-024-02515-1
Funding for this research was provided by:
Ono Pharmaceutical
Bristol Myers Squibb
Article History
Received: 30 October 2023
Accepted: 13 March 2024
First Online: 6 June 2024
Declarations
:
: Kenji Hiraizumi, Chikara Honda, Ayu Watanabe, Takafumi Nakao, and Takahiko Sakamoto are employees of Ono Pharmaceutical Co., Ltd. Shuichi Midorikawa, Hiromi Abe, Nobuki Matsui, and Tsunehisa Yamamoto are employees of Bristol-Myers Squibb K.K. and hold stock or stock options in Bristol Myers Squibb.
: As explained in the original reports [–], each PMS conformed to the Japanese Good Post-Marketing Study Practice (GPSP) regulations. Each participating hospital agreed to contracts for each surveillance with the study sponsor. No intervention was made for the purpose of this study; therefore, no written informed consent was required from each patient. The publication of the original PMS and the use of the information in this study were carried out within the Japanese GPSP regulations. Data were used from the participating institutions that consented to data posting.